Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer.
Jacobs F, Agostinetto E, Miggiano C, De Sanctis R, Zambelli A, Santoro A. Jacobs F, et al. Among authors: agostinetto e. Cancers (Basel). 2023 May 26;15(11):2933. doi: 10.3390/cancers15112933. Cancers (Basel). 2023. PMID: 37296893 Free PMC article. Review.
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. de Azambuja E, et al. Among authors: agostinetto e. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19. ESMO Open. 2023. PMID: 36681013 Free PMC article. Clinical Trial.
Reply to S. Di Cosimo et al.
Agostinetto E, Venet D, Ignatiadis M, Kalashnikova E. Agostinetto E, et al. JCO Precis Oncol. 2023 Jan;7:e2200644. doi: 10.1200/PO.22.00644. JCO Precis Oncol. 2023. PMID: 36701653 No abstract available.
HER2-Low Breast Cancer: Where Are We?
Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M. Molinelli C, et al. Among authors: agostinetto e. Breast Care (Basel). 2022 Dec;17(6):533-545. doi: 10.1159/000527391. Epub 2022 Oct 6. Breast Care (Basel). 2022. PMID: 36590146 Free PMC article. Review.
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, Fabi A, Rimanti A, Michelotti A, Mansutti M, Russo A, Montemurro F, Frassoldati A, Durando A, Gori S, Turletti A, Tamberi S, Urracci Y, Fregatti P, Razeti MG, Caputo R, De Angelis C, Sanna V, Gasparini E, Agostinetto E, de Azambuja E, Poggio F, Boni L, Del Mastro L. Lambertini M, et al. Among authors: agostinetto e. EClinicalMedicine. 2023 May 12;59:101931. doi: 10.1016/j.eclinm.2023.101931. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37256095 Free PMC article.
[Complementary and alternative medicine in oncology].
Bozza C, Agostinetto E, Gerratana L, Puglisi F. Bozza C, et al. Among authors: agostinetto e. Recenti Prog Med. 2015 Dec;106(12):601-7. doi: 10.1701/2094.22648. Recenti Prog Med. 2015. PMID: 26780069 Review. Italian.
Do platinum salts fit all triple negative breast cancers?
Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F. Gerratana L, et al. Among authors: agostinetto e. Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11. Cancer Treat Rev. 2016. PMID: 27343437 Review.
73 results